Active Substance: Ticlopidine HCl.
Overview
Welcome to Dwaey, specifically on PREVOC 250mg page.
This medicine contains an important and useful components, as it consists of
Ticlopidine HClis available in the market in concentration
Ticlopidine Hydrochloride
Patients with increased risk of bleeding from trauma, surgery or pathological disorder. Moderate to severe renal impairment. May need to stop therapy 10-14 days before elective surgery. Full blood counts should be performed prior to therapy and every 2 wk during the first 3 mth of treatment. Pregnancy. Lactation: not known whether excreted in breast milk, discontinue drug or do not nurse
Hereditary hemorrhagic telangiectasia, Intermittent claudication, Ischaemic heart disease
Pre-existing or history of blood dyscrasias; haemostatic disorder or active pathological bleeding (eg. bleeding peptic ulcer, intracranial bleeding); severe hepatic dysfunction. Hypersensitivity. Lactation.
>10% Diarrhea (12.5%) 1-10% Elevated alkaline phosphatase (7.6%),Nausea (7%),Dyspepsia (7%),Rash (5%),GI pain (3.7%),Elevated AST/SGOT (3.1%),Neutropenia (2.4%),Purpura (2.2%),Vomiting (1.9%),Flatulence (1.5%),Pruritus (1.3%),Dizziness (1%),Abnormal LFTs (1%),Anorexia (1%) <1% Agranulocytosis,Aplastic anemia,Pancytopenia,TTP Potentially Fatal: Neutropenia, agranulocytosis, thrombotic thrombocytopenic purpura and aplastic anaemia.
2
Ticlopidine inhibits adenosine diphosphate-mediated platelet aggregation.
Reduced clearance with cimetidine; corticosteroid may antagonise effects on bleeding time. Avoid concurrent use with clopidogrel. Potentially Fatal: Risk of haemorrhage increased with NSAIDs and oral anticoagulants; decreased metabolism of theophylline, phenytoin and bupropion.
Information not available